‘Pharmaceutical’ Controls, Lower Costs: Future Of Cannabinoid Ingredients In Biosynthesis?
Synthetics are necessary for drugs containing cannabinoids because the active ingredient must be consistent from dose to dose. Cannabinoids extracted from hemp vary from plant to plant and more widely from crop to crop, but consistency should matter for cannabinoids used as dietary ingredients, says BioMedican president Dennis O’Neill.
You may also be interested in...
Hemp-Derived CBD bill either provides exact solution US needs for lawful use of cannabinoids as dietary ingredients or falls well short, depending on the trade group. Legislation to expand health savings accounts to include vitamin, mineral and supplement products reached Senate floor vote before failing.
Among four FDA regulatory items withdrawn from OMB review is “Cannabidiol Enforcement Policy; Draft Guidance for Industry,” which the agency submitted in July 2020.
FDA commissioner’s office representative Joseph Franklin explained, as other agency officials have previously, at FDLI confereice that determining whether to make lawful cannabinoids’ use in products other than drugs is both a priority and a challenge.